Renal complications of Fabry disease in children
- PMID: 22898981
- PMCID: PMC3811930
- DOI: 10.1007/s00467-012-2222-9
Renal complications of Fabry disease in children
Abstract
Fabry disease is an X-linked α-galactosidase A deficiency, resulting in accumulation of glycosphingolipids, especially globotriaosylceramide, in cells in different organs in the body. Renal failure is a serious complication of this disease. Fabry nephropathy lesions are present and progress in childhood while the disease commonly remains silent by routine clinical measures. Early and timely diagnosis of Fabry nephropathy is crucial since late initiation of enzyme replacement therapy may not halt progressive renal dysfunction. This may be challenging due to difficulties in diagnosis of Fabry disease in children and absence of a sensitive non-invasive biomarker of early Fabry nephropathy. Accurate measurement of glomerular filtration rate and regular assessment for proteinuria and microalbuminuria are useful, though not sensitive enough to detect early lesions in the kidney. Recent studies support the value of renal biopsy in providing histological information relevant to kidney function and prognosis, and renal biopsy could potentially be used to guide treatment decisions in young Fabry patients. This review aims to provide an update of the current understanding, challenges, and needs to better approach renal complications of Fabry disease in children.
Figures



Similar articles
-
Anderson-Fabry disease: a multiorgan disease.Curr Pharm Des. 2013;19(33):5974-96. doi: 10.2174/13816128113199990352. Curr Pharm Des. 2013. PMID: 23448451 Review.
-
Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.J Hum Genet. 2016 Nov;61(11):923-929. doi: 10.1038/jhg.2016.78. Epub 2016 Jun 23. J Hum Genet. 2016. PMID: 27334365
-
Assessment of renal pathology and dysfunction in children with Fabry disease.Clin J Am Soc Nephrol. 2010 Feb;5(2):365-70. doi: 10.2215/CJN.08091109. Epub 2010 Jan 7. Clin J Am Soc Nephrol. 2010. PMID: 20056758 Free PMC article. Review.
-
Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.Nephron. 2015;129(1):16-21. doi: 10.1159/000369309. Epub 2014 Dec 17. Nephron. 2015. PMID: 25531941
-
The Changing Landscape of Fabry Disease.Clin J Am Soc Nephrol. 2020 Apr 7;15(4):569-576. doi: 10.2215/CJN.09480819. Epub 2020 Mar 4. Clin J Am Soc Nephrol. 2020. PMID: 32132142 Free PMC article. Review. No abstract available.
Cited by
-
A case of Fabry nephropathy with histological features of oligonephropathy.Eur J Pediatr. 2014 Aug;173(8):1111-4. doi: 10.1007/s00431-013-2118-0. Epub 2013 Aug 3. Eur J Pediatr. 2014. PMID: 23913314
-
Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype.Mol Genet Metab Rep. 2022 Feb 17;31:100851. doi: 10.1016/j.ymgmr.2022.100851. eCollection 2022 Jun. Mol Genet Metab Rep. 2022. PMID: 35242583 Free PMC article.
-
IgA nephropathy suspected to be combined with Fabry disease or Alport syndrome: a case report.J Int Med Res. 2020 Mar;48(3):300060519891290. doi: 10.1177/0300060519891290. Epub 2019 Dec 16. J Int Med Res. 2020. PMID: 31840555 Free PMC article.
-
Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants.JIMD Rep. 2021 Jan 27;59(1):60-68. doi: 10.1002/jmd2.12201. eCollection 2021 May. JIMD Rep. 2021. PMID: 33977031 Free PMC article.
-
Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry.Clin Kidney J. 2024 Jul 2;17(8):sfae194. doi: 10.1093/ckj/sfae194. eCollection 2024 Aug. Clin Kidney J. 2024. PMID: 39139182 Free PMC article.
References
-
- Tsutsumi O, Sato M, Sato K, Mizuno M, Sakamoto S. Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected with Fabry’s disease. Asia Oceania J Obstet Gynaecol. 1985;11:39–45. - PubMed
-
- Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res. 2008;64:550–555. - PubMed
-
- Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24:2102–2111. - PMC - PubMed
-
- Meroni M, Spisni C, Tazzari S, Di Vito R, Stingone A, Bovan I, Torri Tarelli L, Sessa A. Isolated glomerular proteinuria as the only clinical manifestation of Fabry’s disease in an adult male. Nephrol Dial Transplant. 1997;12:221–223. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases